Study of TQB2303 in Patients With CD20-Positive Diffuse Large B-cell Lymphoma (DLBCL)

Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Study ID
NCT03777085
Phase
PHASE3
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • TQB2303 — DRUG
    375mg/m2, iv q3w,6 cycles(each cycle is 3 weeks
  • Rituximab — DRUG
    375mg/m2, iv q3w,6 cycles(each cycle is 3 weeks

Study Details

The Purpose of This Study is to Compare the Efficacy, Safety, Immunogenicity and Pharmacokinetics between TQB2303 and Rituximab in Combination With CHOP in Previously Untreated Patients with Diffuse Large B-cell Lymphoma

Key Dates

Start date
Jan 10, 2019
Status verified
May 2019
Primary completion
Dec 30, 2020
Completion
Dec 30, 2020

Study Design

Enrollment
230 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: TQB2303
  • Active Comparator: Rituximab

Primary Outcome Measure

Overall response rate (ORR) [ Time Frame: 18 weeks ]

Related Studies